Suzuki Motor Corp $7269.T recently encountered significant operational challenges after suspending production of its popular Swift model. The interruption, which began on May 26 and extended until June 12, was a direct consequence of a critical shortage in spare parts. According to company announcements, partial production will resume on June 13 with the full cycle expected to restart from June 16. Reports from local media indicate that China’s restrictions on the export of rare earth elements, essential for both internal combustion engines and electric vehicle components, have caused widespread disruptions in the supply chain.

Broadcom Inc. $AVGO has reinforced its position on the AI technology map by commencing shipments of its latest Tomahawk 6 switch chip, targeting the intensifying demand for artificial intelligence processing in data centers. This strategic expansion into AI-focused networking hardware aligns with the surging investment trend in next-generation computing systems.

Sanofi and Regeneron Pharmaceuticals faced notable share price declines after mixed results from late-stage clinical trials of their experimental drug, itepekimab, targeting chronic obstructive pulmonary disease (COPD) in former smokers. On Friday, Sanofi disclosed that its phase III trials produced diverging efficacy data. In one study, the drug demonstrated a 27% reduction in the rate of COPD exacerbations, suggesting meaningful therapeutic potential. However, parallel research failed to replicate these benefits, despite earlier, more positive interim outcomes.